Double-Target CAR-T therapy takes on tough blood cancers
NCT ID NCT04186520
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and evaluate safety and effectiveness using different manufacturing timelines. It is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bispecific anti-CD19 anti-CD20 CAR-T cells (CAR-20/19-T cells)
What this could lead to
If successful, this could offer a more effective treatment option for people with hard-to-treat B-cell cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin and Froedtert Hospital
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••